{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=25",
    "query": {
      "intervention": "SC",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 3860,
    "total_pages": 386,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T07:56:07.739Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00296465",
      "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "InFertility"
      ],
      "interventions": [
        {
          "name": "Pulsatile gonadotropin-releasing hormone (GnRH)",
          "type": "DRUG"
        },
        {
          "name": "Clomiphene Citrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo Pulsatile GnRH",
          "type": "DRUG"
        },
        {
          "name": "Placebo Clomiphene Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 132,
      "start_date": "2005-02",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2011-05-19",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 1,
      "location_summary": "Metairie, Louisiana",
      "locations": [
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00296465"
    },
    {
      "nct_id": "NCT05712200",
      "title": "Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation (AF)"
      ],
      "interventions": [
        {
          "name": "Abelacimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Anthos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2022-12-27",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 174,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 143 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05712200"
    },
    {
      "nct_id": "NCT04249232",
      "title": "Abaloparatide and Pelvic Fracture Healing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fracture of Pelvis (Disorder)"
      ],
      "interventions": [
        {
          "name": "Abaloparatide 80 micrograms per Pen dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo prefilled injector pen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-09-17",
      "completion_date": "2024-04-25",
      "has_results": false,
      "last_update_posted_date": "2024-06-14",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 3,
      "location_summary": "New York, New York • Valhalla, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249232"
    },
    {
      "nct_id": "NCT06832189",
      "title": "EVR and EPO for Liver Transplant Tolerance",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Transplant"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-01-21",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Chicago, Illinois • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06832189"
    },
    {
      "nct_id": "NCT01787474",
      "title": "Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim-sndz",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2014-05-19",
      "completion_date": "2021-06-17",
      "has_results": false,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01787474"
    },
    {
      "nct_id": "NCT02106897",
      "title": "Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "BIIB059 (litifilimab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2014-04-30",
      "completion_date": "2016-05-24",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 5,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02106897"
    },
    {
      "nct_id": "NCT02340234",
      "title": "A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TCS Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 212,
      "start_date": "2015-05",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2017-10-02",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02340234"
    },
    {
      "nct_id": "NCT01544998",
      "title": "Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Nesiritide",
          "type": "DRUG"
        },
        {
          "name": "Tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Saline load",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 43,
      "start_date": "2012-02",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2018-03-22",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01544998"
    },
    {
      "nct_id": "NCT05362058",
      "title": "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin Efsitora Alfa",
          "type": "DRUG"
        },
        {
          "name": "Insulin Degludec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 928,
      "start_date": "2022-06-03",
      "completion_date": "2024-04-10",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 30,
      "location_summary": "Escondido, California • Fresno, California • Greenbrae, California + 27 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05362058"
    },
    {
      "nct_id": "NCT07223840",
      "title": "A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoking"
      ],
      "interventions": [
        {
          "name": "Brenipatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 222,
      "start_date": "2025-11-03",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-28T07:56:07.739Z",
      "location_count": 18,
      "location_summary": "Rogers, Arkansas • DeLand, Florida • Hollywood, Florida + 15 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223840"
    }
  ]
}